687 F.Supp.3d 604
D.N.J.2023Background
- Securities‑fraud class action against Perrigo Company PLC, CEO Joseph C. Papa, and CFO Judy Brown alleging (1) an illegal generic‑drug price‑fixing scheme and misstatements about generic pricing ("Generic Rx Claim") and (2) misrepresentations about the success of Perrigo’s acquisition/integration of Omega Pharma ("Omega Integration Claim").
- Court previously dismissed two other theories (Tysabri and Organic Growth) and narrowed the case to the Generic Rx and Omega Integration claims. Extensive discovery followed, including a Deferred Prosecution Agreement for Sandoz and a State Attorneys General complaint documenting communications among industry participants.
- Defendants moved for summary judgment and Perrigo moved to exclude Plaintiffs’ experts; parties submitted voluminous evidence and expert reports; Daubert hearings were deferred.
- Court holdings: granted summary judgment for Brown in full (all claims against her dismissed); granted Papa’s motion in part (Papa wins on the Generic Rx claim) and denied in part (genuine issues remain on Omega integration statements); denied in part and reserved in part on Perrigo’s motion, including reservation on corporate scienter and on expert exclusion pending Daubert hearings.
- Key legal tensions: whether plaintiffs produced sufficient direct/circumstantial evidence of collusion and of individual scienter for Papa/Brown; and whether corporate (collective) scienter can be imputed to Perrigo at the summary‑judgment/liability stage.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Existence of price‑fixing / falsity of Generic Rx statements | Perrigo engaged in collusion with competitors (DPA, State AG complaint, witness affidavits, parallel price spikes); failure to disclose rendered pricing statements false/misleading | Evidence at best shows oligopoly/parallel conduct and internal documents that mirror public statements; no direct proof Perrigo colluded | Court finds genuine dispute that a price‑fixing conspiracy existed as to Perrigo (material fact for jury) but grants summary judgment for Papa on Generic Rx due to lack of individual scienter; reserves on Perrigo corporate liability pending further briefing on corporate scienter |
| Scienter for Judy Brown (Generic Rx & Omega) | Brown answered analyst questions and received internal reports/penalty data and attended industry events—supports inference she knew or recklessly ignored collusion/integration problems | Brown lacked pricing authority, was not on pricing committee, and internal docs she saw supported her public statements; conflicting integration reports undercut inference of recklessness | Court grants summary judgment for Brown (no scienter; all claims against Brown dismissed) |
| Scienter for Joseph Papa (Generic Rx & Omega) | Papa touted flat‑to‑up‑slightly pricing while aware of dramatic price hikes and competitor activity; attended industry meetings; customer complaints put him on notice | Papa wasn’t on pricing committees; internal documents were consistent with his public statements; Rule 10b5‑1 trades and prior trading pattern undercut motive; many challenged comments were portfolio‑level, not categorical | Court grants Papa’s motion as to the Generic Rx claim (no scienter/misleadingness) but denies as to Omega integration—genuine issues of falsity and scienter remain for jury |
| Corporate scienter / imputation to Perrigo | Plaintiffs invoke collective/corporate scienter to impute knowledge from employees (Boothe, Wesolowski, Polman) and State AG allegations to Perrigo | Defendants argue corporate scienter is a pleading doctrine, plaintiffs failed to connect employee knowledge to the challenged speakers or statements, and individual scienter of Papa/Brown lacking prevents imputation | Court finds plaintiffs did not adequately develop imputation theory at summary judgment, reserves decision and orders additional briefing; court expresses inclination that Perrigo lacks imputed scienter absent stronger connective proof |
| Loss causation & expert proof | Plaintiffs’ event‑study and expert opines corrective disclosures (e.g., Papa’s resignation linked to Omega problems) caused market losses | Perrigo points to competing causes, disputes experts’ methods, and moves to exclude experts | Court denies summary judgment on loss causation (factual disputes, conflicting expert reports, and pending Daubert issues); reserves expert‑exclusion rulings pending hearings |
Key Cases Cited
- Celotex Corp. v. Catrett, 477 U.S. 317 (summary judgment burden on moving party)
- Matsushita Elec. Indus. Co. v. Zenith Radio Corp., 475 U.S. 574 (no reasonable jury could find for nonmoving party where record incapable of supporting verdict)
- Scott v. Harris, 550 U.S. 372 (court may disregard implausible factual narratives utterly discredited by the record)
- Basic Inc. v. Levinson, 485 U.S. 224 (materiality: information a reasonable investor would consider important)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (scienter requirement for §10(b)/Rule 10b‑5 claims)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (standard for inferring scienter)
- In re Ikon Office Solutions, Inc., 277 F.3d 658 (recklessness as extreme departure from ordinary care)
- Novak v. Kasaks, 216 F.3d 300 (scienter through access to contradicting information)
- EP Medsystems, Inc. v. EchoCath, Inc., 235 F.3d 865 (loss causation usually reserved for jury)
- McCabe v. Ernst & Young, LLP, 494 F.3d 418 (plaintiff must prove misrepresentation proximately caused economic loss)